murphyRobert (2).jpg

PS2: Lipidomics/Metabolomics
Mass Spectrometric Approaches to Lipidomic Studies


Prof. Robert Murphy
University of Colorado School of Medicine

United States of America

Robert C. Murphy, Professor, Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, graduated from the Massachusetts Institute of Technology with a Ph.D. in chemistry and is currently a University Distinguished Professor at the University of Colorado. He has worked in the area of mass spectrometry and eicosanoid biochemistry for over 40 years with much of his research activities centered on the use of mass spectrometry to studies of arachidonic acid biochemistry and formation of the biologically active leukotriene mediators. His interests also include the structural characterization of bioactive lipid products derived from the reaction of reactive oxygen species with cellular lipids. Over 500 peer-reviewed papers in scientific journals and several books concerning the mass spectrometry of lipids have been authored by him. He served as President of the American Society for Mass Spectrometry and is on the editorial boards of numerous scientific journals in biochemistry and mass spectrometry. He has received several awards including the Dean’s Mentoring Award, the Faculty Excellence in Teaching Award, an NIH Merit Award, and the Eicosanoid Research Foundation Outstanding Achievement Award and was appointed as a University of Colorado Distinguished Professor. His most recent research programs focused on details of transcellular biosynthesis of leukotrienes, the formation of biologically active lipid products, the advancement of mass spectrometry in the area of lipidomics analysis, and the imaging of complex lipids in tissues.


nb head shot 2 061313.jpg

PS7: Neuropathology and Aging
The elovanoids: a novel class of mediators that arise from elongated omega-3 fatty acids and target neuronal pro-homeostatic signaling hubs

Prof. Nicolas G. Bazan
Louisiana State University Medical Center
United States of America

Nicolas G. Bazan is a neuroscientist and eye researcher, author, educator, mentor, developer, music enthusiast, and art lover. His research focuses on neurodegenerative diseases, aiming to understand endogenous modulation of neuroinflammatory signaling and of cell survival using cellular, molecular, and disease models including lipidomics. His lifelong quest has been to pin down events amenable to translation to help people affected by stroke, Alzheimer's disease, pain, blindness, and other diseases. Nicolas G. Bazan was born in Los Sarmientos, TucumanArgentina on May 22, 1942. He received his MD from the University of Tucuman School of Medicine, Argentina (1965) and was a postdoctoral fellow at Columbia University's College of Physicians and Surgeons and Harvard Medical School (1965–1968). The research that he performed at Harvard was the basis for his Doctor in Medical Sciences thesis (University of Tucuman, 1971). He became the founding director of the LSUHSC Neuroscience Center of Excellence in 1989.


Schunck-photo.jpg

PS20: Lipid Therapeutics
Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases

Dr. Wolf-Hagen Schunck
Max Delbrueck Center for Molecular Medicine
Germany


Wolf Schunck is head of the Eicosanoid Laboratory at the Max Delbrueck Center for Molecular Medicine in Berlin. After studying biochemistry at the Martin-Luther-University in Halle, his research has been mainly focused on the structure and function of cytochrome P450 enzymes and their role in the formation of bioactive lipid mediators. Collaborating both with clinicians and chemists, he served as principal investigator of translational projects in cardiology and nephrology and supported the development and application of targeted lipidomics approaches. He has authored more than 100 papers, is an academic editor of PLOS One, and member of the Editorial Board of the Journal of Lipid Research. Wolf Schunck is co-founder and Board member of OMEICOS Therapeutics, Berlin, Germany, and its subsidiary OMEICOS Ophthalmics, Boston, Massachusetts – two start-up companies developing novel eicosanoid mimetics for the treatment of cardiovascular and eye diseases.


lovinger.jpg

PS15: Endocannabinoids
Endocannabinoid Roles in Brain Function and Behavior

Prof. David Lovinger
Senior Investigator
National Institutes of Health
United States of America

Dr. Lovinger received a B.A. in Psychology from the University of Arizona in 1981 and a Ph.D. in Psychology from Northwestern University in 1987. At Northwestern, he worked with Dr. Aryeh Routtenberg studying the roles of Protein Kinase C and its substrate, the GAP-43/F1 protein, in hippocampal long-term potentiation. His postdoctoral research at the NIAAA focused on the effects of alcohol on ligand-gated ion channels. In 1991 Dr. Lovinger moved to the Vanderbilt University School of Medicine as an Assistant Professor, where in 1998 he rose to the rank of Professor. At Vanderbilt he was also the Deputy Director for Biomedical Science and the Director of the Neuroscience Core within the Kennedy Center. Dr. Lovinger joined the NIAAA in 2001 as a Senior Investigator and Chief of the Laboratory of Integrative Neuroscience. His laboratory is currently studying the modulation and plasticity of synaptic transmission at corticostriatal synapses and the mechanisms by which abused substances effect synaptic transmission.


Hammock Head.jpg

PS21: Oxydized Lipids
Increasing epoxides of polyunsaturated fatty acids blocks pain and resolves inflammation by modulating the ER stress axis.

Prof.  Bruce Hammock
Department of Entomology & UCD Comprehensive Cancer Center
Director, NIEHS-UCD Superfund Research Program
PI, NIH Biotechnology Training Program